CLOSE
MENU

Bausch + Lomb Corporation Is Now Trading Under BLCO Ticker!

MAY 6, 2022

As you may have seen, Bausch + Lomb Corporation began trading today on the New York Stock Exchange and Toronto Stock Exchange under the ticker BLCO.1

This is a tremendous milestone for our company, and gets us closer to our ambitious goal of providing as many patients as possible around the globe with a lifetime of healthy vision. What first began in 1853 as a small optical goods shop in Rochester, New York, is now a fully integrated eye care company – inclusive of Vision Care, Consumer Health Care, Surgical and Ophthalmic Pharmaceuticals – that is well positioned to support consumers, eye care professionals and patients across the full spectrum of eye health.

For nearly two centuries, Bausch + Lomb has remained focused on advancing eye health for people all over the world, pioneering hundreds of innovations. While eye care has evolved, our relentless work to bring innovations to help patients improve their quality of sight has only grown stronger. Today, that legacy of innovation continues through our comprehensive portfolio of more than 400 products, which includes contact lenses, lens and eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments.

Additionally, through our inherent culture of resourcefulness and continued investment in future innovations, our research and development, quality, manufacturing and commercial teams work hand-in-hand each day to fulfil the unmet needs in the industry.

We have a substantial pipeline in various stages of pre-clinical and clinical development, including new over-the-counter eye care products, contact lenses, innovative software and prescription medications for myopia management, next-generation cataract and LASIK surgical equipment, premium intraocular lenses, investigational treatments for dry eye and preservative-free formulations of a range of eye drops.

Together with this team and our approximately 12,000 employees around the globe, we remain steadfast in our commitment to protect and enhance the gift of sight for millions of people around the world – from the moment of birth through every phase of life.


Best regards,

Joseph C. Papa
Chief Executive Officer
Bausch + Lomb

1The common shares have been approved for listing on the New York Stock Exchange (“NYSE”) and conditionally approved for listing on the Toronto Stock Exchange (“TSX”). The common shares begin trading on the NYSE and on an “if, as and when issued basis” on the TSX on May 6, 2022; and the IPO is expected to close on May 10, 2022, subject to customary closing conditions.

]]>